havas Content printed form Havas - The Download - https://download.havas.com/posts/budding-business-at-havas-ecs/
Agency Life

Budding Business at Havas ECS

Budding Business at Havas ECS

Danielle Smith

Danielle Smith

August 28, 2019

How Havas ECS is pioneering the cannabis market through education

"The mission of Havas ECS is to help close any gaps in education."

Havas Endocannabinoid Sciences (ECS) Managing Director Rob Dhoble shares the mission, method and medical needs behind a deeper understanding of cannabis in the US market. The recently launched, educationally focused cannabis consultancy will work closely with Havas Health & You to bring cutting-edge care to consumers while driving the best results for clients who are battling a lack of understanding and acceptance in the growing cannabis market. 

Mark your calendars for Friday, November 15 to attend Medical Cannabis: The Science. The Research. The Risks conference bringing together NYC physicians and industry leaders. 

 

What is the mission of Havas ECS?

Havas ECS serves to advance the understanding of human health and wellness, with science-based education and communication programs that better inform the treatment of individuals with endocannabinoid system-related medical conditions. The endocannabinoid system is a core regulator of health and wellness that was only discovered in the mid-1990s. It is still largely absent from US medical, pharmacy, and nursing school education. The mission of Havas ECS is to help close any gaps in education.

 

How did the idea for Havas ECS come to fruition?

It happened through the appreciation of two developments. First, there was sustained growth in the US and international clinical research regarding the efficacy and safety of botanical cannabinoids (CBD, CBG, BCN, THC, etc.), as well as synthetic cannabinoids produced from organic chemistry. Second, there was European approval of medications such as Sativex®, US approval of Epidiolex®, and the fact that there were multiple companies with cannabinoid drugs in development.

 

How does federal legalization of cannabis affect the work of Havas ECS, if at all?

Cannabis consists of hemp-based and marijuana-based products. Certain hemp-based CBD products are now legally available, although with significant restrictions on health and medical claims unless they are approved Rx drugs. Marijuana is still federally illegal, though medical marijuana has been legalized by 33 in the US states, and by 23 other countries. Havas ECS supports the educational needs of clients engaged in legal cannabis businesses and cannabinoid medicine businesses worldwide.

"Confusion regarding cannabis science is related to the lack of education among health professionals."

Why is there a gap between the hype of cannabis products and the understanding of the scientific basis supporting the use of cannabinoid and cannabis products?

Historically, there has been a decades-long ban on cannabis research in the US. Many believe confusion regarding cannabis science is related to the lack of education among health professionals, and the inability of hemp and cannabis manufacturers to include such science in their promotion because these are not FDA-approved Rx drugs. To fill this gap, data from a seemingly endless supply of anecdotal media reports, pre-clinical studies, and international clinical trials are being used to describe the scientific value of cannabis.

There is a large focus on education at Havas ECS. Can you share a little about what that education will look like? Will it include ads on TV, social media, all of the above?

Havas ECS education includes live events and online training programs for health professionals, patients, and consumers. Live events include a planned full-day cannabinoid medicine educational event for New York City-area physicians, focusing on patient care in an ever-changing medical-legal environment.

The conference Medical Cannabis: The Science. The Research. The Risks will take place on Friday, November 15, at Columbia University, with a focus on the coordination of cannabis self-care with medical care, and the importance of a common glossary to enjoin patient and physician in common treatment understanding. Other topics include endocannabinoid system knowledge among medical providers, current cannabis legislation, and a fact-based liability case study/mock trial learning approach.

 

For more information, those who are interested can email brooke.stone@havas.com

"The mission of Havas ECS is to help close any gaps in education."

Havas Endocannabinoid Sciences (ECS) Managing Director Rob Dhoble shares the mission, method and medical needs behind a deeper understanding of cannabis in the US market. The recently launched, educationally focused cannabis consultancy will work closely with Havas Health & You to bring cutting-edge care to consumers while driving the best results for clients who are battling a lack of understanding and acceptance in the growing cannabis market. 

Mark your calendars for Friday, November 15 to attend Medical Cannabis: The Science. The Research. The Risks conference bringing together NYC physicians and industry leaders. 

 

What is the mission of Havas ECS?

Havas ECS serves to advance the understanding of human health and wellness, with science-based education and communication programs that better inform the treatment of individuals with endocannabinoid system-related medical conditions. The endocannabinoid system is a core regulator of health and wellness that was only discovered in the mid-1990s. It is still largely absent from US medical, pharmacy, and nursing school education. The mission of Havas ECS is to help close any gaps in education.

 

How did the idea for Havas ECS come to fruition?

It happened through the appreciation of two developments. First, there was sustained growth in the US and international clinical research regarding the efficacy and safety of botanical cannabinoids (CBD, CBG, BCN, THC, etc.), as well as synthetic cannabinoids produced from organic chemistry. Second, there was European approval of medications such as Sativex®, US approval of Epidiolex®, and the fact that there were multiple companies with cannabinoid drugs in development.

 

How does federal legalization of cannabis affect the work of Havas ECS, if at all?

Cannabis consists of hemp-based and marijuana-based products. Certain hemp-based CBD products are now legally available, although with significant restrictions on health and medical claims unless they are approved Rx drugs. Marijuana is still federally illegal, though medical marijuana has been legalized by 33 in the US states, and by 23 other countries. Havas ECS supports the educational needs of clients engaged in legal cannabis businesses and cannabinoid medicine businesses worldwide.

"Confusion regarding cannabis science is related to the lack of education among health professionals."

Why is there a gap between the hype of cannabis products and the understanding of the scientific basis supporting the use of cannabinoid and cannabis products?

Historically, there has been a decades-long ban on cannabis research in the US. Many believe confusion regarding cannabis science is related to the lack of education among health professionals, and the inability of hemp and cannabis manufacturers to include such science in their promotion because these are not FDA-approved Rx drugs. To fill this gap, data from a seemingly endless supply of anecdotal media reports, pre-clinical studies, and international clinical trials are being used to describe the scientific value of cannabis.

There is a large focus on education at Havas ECS. Can you share a little about what that education will look like? Will it include ads on TV, social media, all of the above?

Havas ECS education includes live events and online training programs for health professionals, patients, and consumers. Live events include a planned full-day cannabinoid medicine educational event for New York City-area physicians, focusing on patient care in an ever-changing medical-legal environment.

The conference Medical Cannabis: The Science. The Research. The Risks will take place on Friday, November 15, at Columbia University, with a focus on the coordination of cannabis self-care with medical care, and the importance of a common glossary to enjoin patient and physician in common treatment understanding. Other topics include endocannabinoid system knowledge among medical providers, current cannabis legislation, and a fact-based liability case study/mock trial learning approach.

 

For more information, those who are interested can email brooke.stone@havas.com

Danielle Smith is the Communications Manager of Havas Group. She’s believes every meal can be tacos if you have tortillas and the heart to try.

contact our office

Call:

Stop by:

Connect:

Cookie Settings